Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

US: Cognitive Functioning Of Long-Term Heavy Cannabis Users Seeking Treatment

Nadia Solowij, PhD, et al

Journal of the American Medical Association

Wednesday 06 Mar 2002

---
Vol. 287, No. 9

Authors: Nadia Solowij, PhD; Robert S. Stephens, PhD; Roger A. Roffman,
DSW; Thomas Babor, PhD, MPH; Ronald Kadden, PhD; Michael Miller, PhD;
Kenneth Christiansen, PsyD; Bonnie McRee, MPH; Janice Vendetti, MPH; for
the Marijuana Treatment Project Research Group




Context

Cognitive impairments are associated with long-term cannabis use, but
the parameters of use that contribute to impairments and the nature and
endurance of cognitive dysfunction remain uncertain.

Objective

To examine the effects of duration of cannabis use on specific areas of
cognitive functioning among users seeking treatment for cannabis
dependence.

Design, Setting, and Participants

Multisite retrospective cross-sectional neuropsychological study
conducted in the United States ( Seattle, Wash; Farmington, Conn; and
Miami, Fla ) between 1997 and 2000 among 102 near-daily cannabis users (
51 long-term users: mean, 23.9 years of use; 51 shorter-term users:
mean, 10.2 years of use ) compared with 33 nonuser controls.

Main Outcome Measures

Measures from 9 standard neuropsychological tests that assessed
attention, memory, and executive functioning, and were administered
prior to entry to a treatment program and following a median 17-hour
abstinence.

Results

Long-term cannabis users performed significantly less well than shorter-
term users and controls on tests of memory and attention. On the Rey
Auditory Verbal Learning Test, long-term users recalled significantly
fewer words than either shorter-term users ( P = .001 ) or controls ( P
= .005 ); there was no difference between shorter-term users and
controls. Long-term users showed impaired learning ( P = .007 ),
retention ( P = .003 ), and retrieval ( P = .002 ) compared with
controls. Both user groups performed poorly on a time estimation task (
P( .001 vs controls ). Performance measures often correlated
significantly with the duration of cannabis use, being worse with
increasing years of use, but were unrelated to withdrawal symptoms and
persisted after controlling for recent cannabis use and other drug use.

Conclusions

These results confirm that long-term heavy cannabis users show
impairments in memory and attention that endure beyond the period of
intoxication and worsen with increasing years of regular cannabis use.

JAMA. 2002;287:1123-1131

In the current climate of debate about marijuana laws and interest in
marijuana as medicine, [1] one issue remains unresolved: Does heavy,
frequent, or prolonged use of cannabis lead to a deterioration in
cognitive function that persists well beyond any period of acute
intoxication? Is the functioning of the brain altered in the long term?
With over 7 million people using cannabis weekly or more often in the
United States alone [2] and the potential for increased physician
recommendations for select patients to use cannabis therapeutically, [1]
answers to these questions are of significant public health concern.
[3, 4] Scientific evidence from past research clearly showed that gross
impairment related to chronic cannabis use did not occur but was
inconclusive with regard to the presence of more specific deficits. [5,
6] Recent studies with improved methods have demonstrated changes in
cognition and brain function associated with long-term or frequent use
of cannabis. Specific impairments of attention, memory, and executive
function have been found in cannabis users in the unintoxicated state (
and in children exposed to cannabis in utero [7] ) in controlled studies
using brain event-related potential techniques6, [8-10] and
neuropsychological assessments [11-15] including complex tasks.

Brain imaging studies of cannabis users have demonstrated altered
function, blood flow, and metabolism in prefrontal and cerebellar
regions. [16-19] Studies failing to detect cognitive decline associated
with cannabis use [20] may reflect insufficient heavy or chronic use of
cannabis in the sample or the use of insensitive assessment instruments.
Impairments appear to increase with duration and frequency of cannabis
use; however, the parameters of use that are associated with short-or
long-lasting cognitive and brain dysfunction have not been fully
elucidated. The attribution of deficits to lingering acute effects,
drug residues, abstinence effects, or lasting changes caused by chronic
use continues to be debated. [5, 6] Animal research suggests an
important role for the cannabinoid receptor in regulating the neural
activity critical for memory processing. [21-24] Long-term use of
cannabis may result in altered functioning of the cannabinoid receptor
and its associated neuromodulator systems.

This study investigated the nature of cognitive impairments associated
with long-term cannabis use employing data collected from a large
clinical trial of chronic users seeking treatment for cannabis
dependence. The study compared 102 cannabis users assessed prior to
treatment on carefully selected neuropsychological tests with 33 nonuser
controls. The parameters of cannabis use that contribute to impairment
were examined. It was hypothesized that performance would deteriorate
as the number of years of regular use increased.

METHODS

Design

A multisite, retrospective, cross-sectional comparison-group design was
used to compare ( 1 ) long-term users with a mean of 23.9 years of
regular cannabis use; ( 2 ) shorter-term users with a mean of 10.2 years
of regular use; and ( 3 ) nonusers of cannabis. Key confounding
variables ( age, IQ, other drug use ) were controlled through matching
or statistical methods. The sample size required for this study was
determined by estimating a 94% chance of detecting a moderate effect
size of 0.5 SD units at a 2-tailed of .05.

Recruitment Procedure and Assessment of Drug Use

Sixty-five of the 102 cannabis users were delayed-treatment participants
from the Marijuana Treatment Project, a multisite US study ( Seattle,
Wash; Farmington, Conn; and Miami, Fla ) conducted between 1997 and 2000
of the effectiveness of brief treatments for cannabis dependence.25 The
remainder were recruited through the Marijuana Treatment Project
specifically for this study. Participants provided written informed
consent as approved by the ethics committees of the participating
institutions and were paid $75 for completing the cognitive assessments.
Controls ( n = 33 ) were recruited from the general population through
media advertisements at only 1 site. The controls were told that the
researchers were studying the effects of exposure to drugs and alcohol
on cognitive functioning, and that at present only individuals at the
lighter end of the spectrum of drug experience were required. The aim
was to minimize cannabis use among controls while approximating the
other characteristics of the cannabis-using sample. Assessors were not
blinded with regard to group assignment. Self-reported drug and alcohol
use were assessed by the Addiction Severity Index,26 a separate
structured interview, and the Time Line Follow Back procedure. [27, 28]
The Structured Clinical Interview for Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition ( DSM-IV ) Axis I Disorders ( SCID )
[29] assessed cannabis dependence. Duration of regular ( at least twice
per month ) cannabis use was an averaged composite measure derived from
the Addiction Severity Index, SCID, and the structured interview.
Current frequency of cannabis use was calculated from the Time Line
Follow Back procedure.

Inclusion/Exclusion Criteria

Cannabis users were included if they had used cannabis regularly for at
least 3 years, were currently using at least once a week, were seeking
treatment to assist them to cease or reduce their use of cannabis, and
were willing to participate in the treatment program offered.
Participants were excluded if they had ever had a serious illness or
injury that may have affected the brain, any psychotic disorder, met a
current DSM-IV diagnosis of dependence on any other drug or alcohol, or
had a poor command of the English language.

Sample Characteristics

Table 1 provides demographic information and cannabis use parameters. (
acquisition ( 3 words over 5 trials ) was greater among long-term users
( 13.7% ) than controls ( 0% ) ( P = .007 ) but not shorter-term users (
5.9% ). The proportion of long-term users recalling fewer than 10 words
on trial V ( 27.5% ) was more than among shorter-term users ( 8.5% ) or
controls ( 3.0% ) ( P = .002 ). Significantly more long-term users (
23.5% ) lost 3 or more words over the 20-minute delay between trials VI
and VII than shorter-term users ( 4.3% ) or controls ( 3.0% ) ( P = .003
). Long-term users showed a smaller primacy effect in the serial
position curve than either other group ( P = .02 ). Groups did not
differ in the recency effect or in words recalled from the middle of the
list.

Users overall and long-term users recognized fewer words than controls
from list A ( overall, P = .03; long-term, P = .01 ) and list B (
overall, P = .01; long-term, P = .04 ) but long-term users did not
differ from shorter-term users. More than half of the long-term users (
55% ) had a recognition score for list A of 12 or less compared with 28%
of shorter-term users and 21% of controls ( P = .002 ). Long-term users
misassigned more words ( median, 2 ) than shorter-term users and
controls ( each median, 0 ) ( P( .001 ). A greater proportion of long-
term users ( 13.7% ) compared with shorter-term users ( 6.4% ) and
controls ( 0% ) actually identified fewer words on recognition than they
had just prior during recall on trial VII ( P = .02 ). Long-term users'
performance was significantly poorer than published norms [47] for the
general population on most measures from the RAVLT.

Stroop Test

Cannabis users did not differ significantly from controls after
inclusion of covariates in any condition or on interference scores.
While there were no performance differences between Color-Word ( CW )
and Color-Read ( CR ) in the control group, performance on CR was,
however, poorer than on CW in both long ( P( .001 ) and shorter-term
users ( P .03 ). Color-Read was the additional interference condition
designed to increase demands on executive function.43 There was an
inverse relationship between duration of cannabis use and number of
items completed on CR ( partial r, - 0.27; P = .003 ) and CW ( partial
r, - 0.27; P = .004 ) after controlling for age and FSIQ. These results
suggest that cannabis users are vulnerable to task complexity with
increasing demands creating more sources of interference that adversely
affect performance.

Wisconsin Card Sorting Test

There were no significant group differences on any Wisconsin Card
Sorting Test ( WCST ) measure but a trend on one: long-term users failed
to maintain the set more often than shorter-term users ( P = .05 ) or
controls ( P = .07 ). Research suggests that this measure best
represents attentional dysfunction. [39] There was no evidence of
impaired performance with increasing years of cannabis use after
controlling for covariates.

Alphabet Task and Omitted Numbers

Groups did not differ in the time taken to complete any trial of the
Alphabet Task or in the number of items correct in the Omitted Numbers
task. The log time to complete the alternating trial of the Alphabet
Task increased as a function of duration of cannabis use ( partial r,
0.26; P = .006 ), as did the square root difference between times taken
to complete the alternating and loud trials, an index of interference
and lack of flexibility ( partial r, 0.26; P = .006 ).

Time Estimation Tasks

Cannabis users differed from controls ( P( .001 ) in Time Estimation
Task A where they estimated the time taken to complete the preceding (
Omitted Numbers ) task. Both long- and shorter-term users
underestimated the time by about one third of the actual time taken (
64.4 seconds ) and differed significantly from controls ( P = .01 and P(
.001, respectively ). Groups did not differ in the simple and brief
warned passive Time Estimation Task B or Time Production, where they
could use strategies such as counting. Time estimation measures did not
correlate with duration of cannabis use.

Auditory Consonant Trigrams

Long-term users recalled significantly fewer items than shorter-term
users ( P = .007 ), controls ( P = .002 ), and published norms [48] on
only the 9-second delay condition. The number of items recalled did not
correlate with duration of cannabis use. In the general population, the
greater the delay interval the worse the performance. In cannabis
users, this general pattern was apparent, though there was greater
interference at the shorter-delay interval than would be expected.

Paced Auditory Serial Addition Test

Long-term users had slower processing rates than shorter-term users on
trial 1 ( P = .007 ), with trends on trial 2 ( P = .03 ) and the total
processing rate across all trials ( P = .02 ). Group differences on all
other measures failed to reach significance but the performance of the
long-term users was poorer in comparison with one set of norms49 but not
another. [50]

Pure Effects Attributable to Cannabis Use and Effects of Recent vs
Chronic Use

Excluding all participants with histories of regular other drug or
alcohol use, dependence or treatment, and controls with any history of
regular cannabis use within the past 20 years reduced the sample to 27
long-term users, 33 shorter-term users, and 26 controls. Despite the
reduction in power to detect differences between groups, there remained
a significant difference with = .05 between long-term users and controls
on RAVLTsum ( P = .03 ), recognition of lists A ( P = .004 ) and B ( P =
.01 ), and between users overall and controls on the unwarned Time
Estimation task ( P = .02 ). These results support the hypothesis that
impaired memory function and time estimation are specific to chronic use
of cannabis.

In a separate analysis, exclusion of users whose urinary cannabinoid
metabolite levels exceeded those from the night before testing by 50
ng/mg or more ( n = 18 ) still resulted in significant differences
between long- and shorter-term users, and long-term users and controls
on RAVLT sum ( P = .002 and P = .002, respectively ), on recognition of
lists A ( P = .005 and P = .006 ) and B ( P = .01 and P( .001 ), on the
9-second delay of the Auditory Consonant Trigrams test ( P = .02 and P =
.03 ), and users still differed from controls on time estimation ( P =
.005 ). When the sample was split at the median for time since last use
or level of urinary cannabinoid metabolite on the day of testing and
analyzed by ANCOVA, there were no differences on any measure between
those who had used cannabis within the past 17 hours and those who had
used cannabis 17 or more hours ago, or those with high vs low levels of
urinary metabolites and no interactions with duration of cannabis use.
Including measures of recent use as covariates in ANCOVA did not change
the significance of differences between long- and shorter-term users.
These results support the hypothesis that impaired performance is not a
consequence of recent use prior to testing or the extent of cannabinoid
residues present.

To explore further the influences of duration of cannabis use and
recency of use, semipartial correlations were calculated using the
following predictors: FSIQ, age, duration of cannabis use, and hours
since last use of cannabis. As shown in Table 4, the unique
contribution of duration of cannabis use to the variance of each test
variable was superior or at least equivalent to that of recency of use
in all 6 test variables that had significant contributions from at least
1 cannabis use parameter. Recent use contributed only to performance on
the memory tests. The fact that a minority of the sample, primarily
shorter-term users, reported experiencing mild withdrawal symptoms, yet
shorter-term users' performance was not impaired, supports the
interpretation of the cognitive impairments observed as a long-term
consequence of cannabis use and not a manifestation of overtly
experienced withdrawal.

COMMENT

The results of this study have confirmed and extended previous findings
of cognitive impairments among chronic heavy cannabis users.

Acknowledgment: We are grateful to Aimee Balmer-Campbell, BA, Kara
Brennan Dion, BA, David Duresky, MA, Dave Ghany, BA, Brian Glidden, BA,
Cara Gluskoter, MS, Cher Gunby, BA, Jennifer Haley, BA, Heather Haynes,
RN, Patricia Holkon, MA, Elise Kabella, PhD, Priscilla Morse, MA, Joe
Picciano, MS, Sam Schwartz, MSW, Megan Swan, MA, Debbie Talamini, AS,
and Anna Wolfe, BA, for input and assistance with data collection and
trial management, Peter Caputi, BA, GradDip, for statistical advice,
Brin Grenyer, PhD, for comments on the manuscript, Eva Congreve, DipLib,
for library assistance, and to all participants in this research.

REFERENCES

1. Watson SJ, Benson JA, Joy JE. Marijuana and medicine: assessing the
science base: a summary of the 1999 Institute of Medicine report. Arch
Gen Psychiatry. 2000;57:547-552.

2. Substance Abuse and Mental Health Services Administration ( SAMHSA
). National Household Survey on Drug Abuse Series: H-6: Preliminary
Results from the 1997 National Household Survey on Drug Abuse.
Rockville, Md: Office on Applied Studies; 1998. DHHS publication SMA
98-3251.

3. Hall W, Babor TF. Cannabis use and public health: assessing the
burden. Addiction. 2000;95:485-490.

4. Voelker R. "Decent research and closure" needed on medical
marijuana, says head of NIH panel. JAMA. 1997;278:802.

5. Pope HG, Gruber AJ, Yurgelun-Todd D. The residual
neuropsychological effects of cannabis: the current status of research.
Drug Alcohol Depend. 1995;38:25-34.

6. Solowij N. Cannabis and Cognitive Functioning Cambridge, England:
Cambridge University Press; 1998.

7. Fried PA, Watkinson B, Gray R. Differential effects on cognitive
functioning in 9- to 12-year olds prenatally exposed to cigarettes and
marihuana. Neurotoxicol Teratol. 1998;20:293-306.

8. Solowij N, Michie PT, Fox AM. Effects of long term cannabis use on
selective attention: an event-related potential study. Pharmacol
Biochem Behav. 1991;40:683-688.

9. Solowij N, Michie PT, Fox AM. Differential impairments of selective
attention due to frequency and duration of cannabis use. Biol
Psychiatry. 1995;37:731-739.

10. Solowij N. Do cognitive impairments recover following cessation of
cannabis use? Life Sci. 1995;56:2119-2126.

11. Pope HG, Yurgelun-Todd D. The residual cognitive effects of heavy
marijuana use in college students. JAMA. 1996;275:521-527.

12. Pope HG, Jacobs A, Mialet JP, Yurgelun-Todd D, Gruber S. Evidence
for a sex-specific residual effect of cannabis on visuospatial memory.
Psychother Psychosom. 1997;66:179-184.

13. Fletcher JM, Page JB, Francis DJ, et al. Cognitive correlates of
long-term cannabis use in Costa Rican men. Arch Gen Psychiatry.
1996;53:1051-1057.

14. Elwan O, Hassan AAH, Naseer MA, et al. Brain aging in a sample of
normal Egyptians: cognition, education, addiction and smoking. J Neurol
Sci. 1997;148:79-86.

15. Solowij N, Grenyer BFS, Peters R, Chesher G. Long term cannabis
use impairs memory processes and frontal lobe function. In: 1997
Symposium on the Cannabinoids. Burlington, Vt: International
Cannabinoid Research Society; 1997:84.

16. Loeber RT, Yurgelun-Todd DA. Human neuroimaging of acute and
chronic marijuana use: implications for frontocerebellar dysfunction.
Hum Psychopharmacol Clin Exp. 1999;14:291-301.

17. Block RI, O'Leary DS, Hichwa RD, et al. Cerebellar hypoactivity in
frequent marijuana users. Neuroreport. 2000;11:749-753.

18. Block RI, O'Leary DS, Hichwa RD, et al. Effects of frequent
marijuana use on memory-related regional cerebral blood flow. Pharmacol
Biochem Behav. In press.

19. Block RI, O'Leary DS, Augustinack JC, et al. Effects of frequent
marijuana use on attention-related regional cerebral blood flow. Abstr
Soc Neurosci. 2000;26:2080.

20. Lyketsos CG, Garrett E, Liang K-Y, Anthony JC. Cannabis use and
cognitive decline in persons under 65 years of age. Am J Epidemiol.
1999;149:794-800.

21. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and
memory. Life Sci. 1999;65:715-723.

22. Hampson RE, Deadwyler SA. Cannabinoids reveal the necessity of
hippocampal neural encoding for short-term memory in rats. J Neurosci.
2000;20:8932-8942.

23. Reibaud M, Obinu MC, Ledent C, et al. Enhancement of memory in
cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol.
1999;379:R1-R2.

24. Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A. Enhanced
long-term potentiation in mice lacking cannabinoid CB1 receptors.
Neuroscience. 2000;95:5-7.

25. Marijuana Treatment Project Research Group. Treating marijuana
dependence: findings from a multi-site study. Arch Gen Psychiatry. In
press.

26. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the
Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.

27. Sobell LC, Sobell MB. Timeline follow-back: a technique for
assessing self reported alcohol consumption. In: Litten RZ, Allen JP,
eds. Measuring Alcohol Consumption: Psychological and Biochemical
Methods. Totowa, NJ: Humana Press; 1992.

28. Miller WR. Form 90: A Structured Assessment Interview for Drinking
and Related Behaviors: Test Manual: Project MATCH Monograph Series, Vol.
5. Bethesda, Md: National Institute on Alcohol Abuse and Alcoholism;
1996. NIH Publication 96-4004.

29. First MB, Gibbon M, Spitzer RL, Williams JB. User's Guide for the
Structured Clinical Interview for DSM-IV Axis I DisordersResearch
Version. New York, NY: Biometrics Research Department, New York State
Psychiatric Institute; 1996.

30. Jastak S, Wilkinson G. The Wide Range Achievement Test: Manual of
Instructions. Wilmington, Del: Jastak Associates; 1984.

31. Kareken DA, Gur RC, Saykin AJ. Reading on the Wide Range
Achievement Test-Revised and parental education as predictors of IQ:
comparison with the Barona formula. Arch Clin Neuropsychol.
1995;10:147-157.

32. Blair JR, Spreen O. Predicting premorbid IQ: a revision of the
National Adult Reading Test. Clin Neuropsychol. 1989;3:129-136.

33. Barona A, Reynolds CR, Chastain R. A demographically based index
of pre-morbid intelligence for the WAIS-R. J Consult Clin Psychol.
1984;52:885-887.

34. Bell R, Taylor EH, Ackerman B, Pappas AA. Interpretation of urine
quantitative 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid to
determine abstinence from marijuana smoking. J Toxicol Clin Toxicol.
1989;27:109-115.

35. Dackis CA, Pottash ALC, Annitto W, Gold MS. Persistence of urinary
marijuana levels after supervised abstinence. Am J Psychiatry.
1982;139:1196-1198.

36. Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A. Excretion
patterns of cannabinoid metabolites after last use in a group of chronic
users. Clin Pharmacol Ther. 1985;38:572-578.

37. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-
9-carboxy-delta-9-tetrahydrocannabinol: a delta-9-THCCOOH to creatinine
ratio study. J Anal Toxicol. 1999;23:531-534.

38. Baddeley A, Emslie H, Nimmo Smith I. The Speed and Capacity of
Language-Processing Test Manual. Bury St Edmonds, England: Thames
Valley Test Co; 1992.

39. Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY:
Oxford University Press; 1995.

40. Rey A. L'examen clinique en psychologie. Paris, France: Presse
Universitaire de France; 1964.

41. Spreen O, Strauss E. A Compendium of Neuropsychological Tests:
Administration, Norms and Commentary. 2nd ed. New York, NY: Oxford
University Press; 1998.

42. Golden CJ. Stroop Color and Word Test: A Manual for Clinical and
Experimental Uses. Wood Dale, Ill: Stoelting; 1978.

43. Bohnen N, Jolles J, Twijnstra A. Modification of the Stroop Color
Word Test improves differentiation between patients with mild head
injury and matched controls. Clin Neuropsychol. 1992;6:178-184.

44. The Wisconsin Card Sorting Test: Computer Version. Alpharetta, Ga:
Psychological Assessment Resources Inc, CyberMetrics Testing Software
Services; 1989.

45. Stuss DT, Stethem LL, Poirier CA. Comparison of three tests of
attention and rapid information processing across six age groups. Clin
Neuropsychol. 1987;1:139-152.

46. Levin HS, Mattis S, Ruff RM, et al. Neurobehavioral outcome
following minor head injury: a three-center study. J Neurosurg.
1987;66:234-243.

47. Geffen G, Moar KJ, O'Hanlon AP, Clark CR, Geffen LB. Performance
measures of 16- to 86-year old males and females on the Auditory Verbal
Learning Test. Clin Neuropsychol. 1990;4:45-63.

48. Stuss DT, Stetham L, Pelchat G. Three tests of attention and rapid
information processing: an extension. Clin Neuropsychol.
1988;2:246-250.

49. Roman DD, Edwall GE, Buchanan RJ, Patton JH. Extended norms for
the Paced Auditory Serial Addition Task. Clin Neuropsychol.
1991;5:33-40.

50. Brittain JL, La Marche JA, Reeder KP, Roth DL, Boll TJ. Effects of
age and IQ on Paced Auditory Serial Addition Task ( PASAT ) performance.
Clin Neuropsychol. 1991;5:163-175.

51. Levy R, Goldman-Rakic PS. Segregation of working memory functions
within the dorsolateral prefrontal cortex. Exp Brain Res.
2000;133:23-32.

52. Herman BP, Seidenberg M, Wyler A, et al. The effects of human
hippocampal resection on the serial position curve. Cortex.
1996;32:323-334.

53. Middleton FA, Strick PL. Anatomical evidence for cerebellar and
basal ganglia involvement in higher cognitive function. Science.
1994;266:458-461.

54. Schacter DL. Memory and awareness. Science. 1998;280:59-60.

55. Schmahmann JD, ed. The Cerebellum and Cognition. San Diego,
Calif: Academic Press; 1997.

56. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor
localization in brain. Proc Natl Acad Sci U S A. 1990;87:1932-1936.


 

 

 

After you have finished reading this article you can click here to go back.




This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!